首页 > 最新文献

艾滋病(英文)最新文献

英文 中文
Prevalence of HIV, HBV and HCV Infections among Sickle Cell Disease Patients in Southwestern Nigeria: A Case-Control Study 尼日利亚西南部镰状细胞病患者中HIV、HBV和HCV感染率的病例对照研究
Pub Date : 2021-08-27 DOI: 10.4236/wja.2021.113009
G. Odaibo, O. Babalola, O. Akpa, Fasola Fa, A. Odetunde, B. Brown, Nanfisat A. Alamukii, C. Babalola, A. Falusi
Aim: This study was designed to determine the prevalence of HBV, HCV and HIV infections among individuals with Sickle Cell Disease (SCD) in Ibadan, southwestern Nigeria. Methodology: In this case-control study, 1017 patients with SCD and 1017 age and gender matched controls were enrolled from 6 health facilities and some communities in Ibadan, southwestern Nigeria. Blood samples were tested for the presence of HIV, HBV and HCV infections. Structured questionnaire was used to capture participants’ information and data analyzed using descriptive statistics, McNemar Chi-square/Fishers exact test. Results: Blood transfusion was significantly more common among SCD cases [566 (55.7%)] than controls [54 (5.3%)], while history of vaccination was higher in the control group (p = 0.001). The overall prevalence of HIV [2 (0.2%) vs 11 (1.1%)], HBV [58 (5.7) vs 66 (6.5%)] and HCV [10 (1.0) vs 22 (2.2%)] was lower among SCD cases than controls, respectively, although significantly different only in HCV infection (p = 0.048). All three infections were significantly higher in adults than in children. Co-infection was found only in four of the participants, all of whom were SCD patients. Conclusion: The prevalence of HIV, HBV and HCV infection among SCD patients indicates an improvement in the transfusion safety measures in the region. The prevalence of HBV and HCV found in this study is still relatively high when compared with reports from some other regions. There is a need for continued surveillance and subsidized cost of drugs for treatment of these infections, especially for SCD patients who already have a compromised immunity.
目的:本研究旨在确定尼日利亚西南部伊巴丹镰状细胞病(SCD)患者中HBV、HCV和HIV感染的流行率。方法:在这项病例对照研究中,1017名SCD患者和1017名年龄和性别匹配的对照者来自尼日利亚西南部伊巴丹的6个卫生机构和一些社区。血液样本检测是否存在HIV、HBV和HCV感染。结构化问卷用于获取参与者的信息和数据,并使用描述性统计、McNemar Chi square/Fishers精确检验进行分析。结果:SCD患者中输血的发生率[566(55.7%)]明显高于对照组[54(5.3%)],而对照组的疫苗接种史更高(p=0.001)。SCD患者的HIV总患病率[2(0.2%)vs 11(1.1%)]、HBV总患病率[58(5.7)vs 66(6.5%)]和HCV总患病率[10(1.0)vs 22(2.2%)]分别低于对照组,尽管仅在HCV感染中有显著差异(p=0.048)。所有三种感染在成人中均显著高于儿童。只有四名参与者同时感染,他们都是SCD患者。结论:SCD患者中HIV、HBV和HCV的感染率表明该地区输血安全措施有所改善。与其他地区的报告相比,本研究中发现的HBV和HCV的患病率仍然相对较高。需要继续监测和补贴治疗这些感染的药物费用,特别是对于已经免疫力受损的SCD患者。
{"title":"Prevalence of HIV, HBV and HCV Infections among Sickle Cell Disease Patients in Southwestern Nigeria: A Case-Control Study","authors":"G. Odaibo, O. Babalola, O. Akpa, Fasola Fa, A. Odetunde, B. Brown, Nanfisat A. Alamukii, C. Babalola, A. Falusi","doi":"10.4236/wja.2021.113009","DOIUrl":"https://doi.org/10.4236/wja.2021.113009","url":null,"abstract":"Aim: This study was designed to determine the prevalence of HBV, HCV and HIV infections among individuals with Sickle Cell Disease (SCD) in Ibadan, southwestern Nigeria. Methodology: In this case-control study, 1017 patients with SCD and 1017 age and gender matched controls were enrolled from 6 health facilities and some communities in Ibadan, southwestern Nigeria. Blood samples were tested for the presence of HIV, HBV and HCV infections. Structured questionnaire was used to capture participants’ information and data analyzed using descriptive statistics, McNemar Chi-square/Fishers exact test. Results: Blood transfusion was significantly more common among SCD cases [566 (55.7%)] than controls [54 (5.3%)], while history of vaccination was higher in the control group (p = 0.001). The overall prevalence of HIV [2 (0.2%) vs 11 (1.1%)], HBV [58 (5.7) vs 66 (6.5%)] and HCV [10 (1.0) vs 22 (2.2%)] was lower among SCD cases than controls, respectively, although significantly different only in HCV infection (p = 0.048). All three infections were significantly higher in adults than in children. Co-infection was found only in four of the participants, all of whom were SCD patients. Conclusion: The prevalence of HIV, HBV and HCV infection among SCD patients indicates an improvement in the transfusion safety measures in the region. The prevalence of HBV and HCV found in this study is still relatively high when compared with reports from some other regions. There is a need for continued surveillance and subsidized cost of drugs for treatment of these infections, especially for SCD patients who already have a compromised immunity.","PeriodicalId":58633,"journal":{"name":"艾滋病(英文)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45224611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Evaluation of Rational Use of Antiretrovirals before the Dolutegravir Transition in Kinshasa, Democratic Republic of Congo 刚果民主共和国金沙萨多卢特格拉韦过渡前抗逆转录病毒药物合理使用的评估
Pub Date : 2021-05-08 DOI: 10.4236/WJA.2021.112004
E. Kamangu, B. Bulanda, Idriss M. Mwanaut, Simplice K. Makoka, G. Mesia
Background: The ultimate goal of AntiRetroViral Treatments (ART) is to achieve complete immune restoration and lasting viral suppression in the infected patient. In order to ensure the efficacy, safety and accessibility of antiretroviral drugs (ARVs), it is recommended that they should be prescribed according to national guidelines; which are evolving with the various recommendations of the World Health Organization (WHO) and the arrival of newer, more effective and safer molecules. Objective: The objective of this study was to assess the rational use of Antiretrovirals in patients treated in Kinshasa before the use of Dolutegravir within the national program in order to assess the correct use of these molecules. Methods: This work is a descriptive cross-sectional study to assess the rational use of first-line ARVs among People Living with HIV (PLHIV) in different Centers of Treatment (ATCs) in Kinshasa before the introduction of Dolutegravir. The records of patients on ARVs were randomly and rationally selected in 12 different ATCs for HIV in Kinshasa according to three centers per district in the period from June to September 2018. Information on use and consumption of ARVs, compliance with guidelines, change of therapeutic combination as well as their reasons were consulted for the present study. Results: 507 files of PLHIV were collected in the various ATCs. 274 (54.1%) were from female patients. The most represented age group was 26 to 35 years with 192 patients (37.9%). The mean duration of first-line treatment for all patients included was 16.30 ± 5.85 months. The most widely used combination of ARVs overall was TDF + 3TC + EFV at 45.4%. 305 (60.2%) PLHIV kept the same first-line treatment molecule throughout the treatment period with an average treatment duration of 12.9 ± 2.77 months. The most common combination found in this population was TDF + 3TC + EFV (69.2%). 202 (39.8%) PLHIV changed treatment molecule yet respecting the first-line combinations. The average duration of treatment for those who changed molecules was 21.43 ± 7.25 months. Before the change, 112 (55.5%) of these patients were using the ZDV + 3TC + EFV combination. After switching, 105 (52%) of the patients used the TDF + 3TC + NVP combination. The first reason for changing molecules was its unavailability (53.3%) in the ATCs. Conclusion: Although some banned molecules are still available in some treatment centers, the guidelines on first-line treatments are respected in different centers in Kinshasa.
背景:抗逆转录病毒治疗(ART)的最终目标是在感染患者中实现完全的免疫恢复和持久的病毒抑制。为了确保抗逆转录病毒药物的疗效、安全性和可及性,建议根据国家指南开具处方;随着世界卫生组织(世界卫生组织)的各种建议以及新的、更有效和更安全的分子的到来,这些分子正在发展。目的:本研究的目的是评估在金沙萨接受治疗的患者在国家计划中使用多卢替格拉韦之前是否合理使用抗逆转录病毒药物,以评估这些分子的正确使用。方法:这项工作是一项描述性的横断面研究,旨在评估在引入多鲁特格拉韦之前,金沙萨不同治疗中心的HIV感染者(PLHIV)对一线抗逆转录病毒药物的合理使用情况。2018年6月至9月期间,在金沙萨的12个不同的HIV ATCs中,根据每个地区的三个中心,随机合理地选择了ARV患者的记录。本研究查阅了抗逆转录病毒药物的使用和消费、遵守指南、改变治疗组合及其原因的信息。结果:在不同的ATCs中收集到507份PLHIV文件。女性患者274例(54.1%)。最具代表性的年龄组为26至35岁,共有192名患者(37.9%)。所有患者的一线治疗平均持续时间为16.30±5.85个月。总体而言,使用最广泛的抗逆转录病毒药物组合是TDF+3TC+EFV,占45.4%。305(60.2%)PLHIV在整个治疗期间保持相同的一线治疗分子,平均治疗时间为12.9±2.77个月。在该人群中发现的最常见的组合是TDF+3TC+EFV(69.2%)。202(39.8%)PLHIV改变了治疗分子,但尊重一线组合。改变分子的患者的平均治疗时间为21.43±7.25个月。在改变之前,这些患者中有112人(55.5%)使用ZDV+3TC+EFV组合。转换后,105名(52%)患者使用TDF+3TC+NVP组合。改变分子的第一个原因是其在ATCs中的不可用性(53.3%)。结论:尽管在一些治疗中心仍然可以获得一些被禁止的分子,但在金沙萨的不同中心都遵守了一线治疗指南。
{"title":"Evaluation of Rational Use of Antiretrovirals before the Dolutegravir Transition in Kinshasa, Democratic Republic of Congo","authors":"E. Kamangu, B. Bulanda, Idriss M. Mwanaut, Simplice K. Makoka, G. Mesia","doi":"10.4236/WJA.2021.112004","DOIUrl":"https://doi.org/10.4236/WJA.2021.112004","url":null,"abstract":"Background: The ultimate goal of AntiRetroViral Treatments (ART) is to achieve complete immune restoration and lasting viral suppression in the infected patient. In order to ensure the efficacy, safety and accessibility of antiretroviral drugs (ARVs), it is recommended that they should be prescribed according to national guidelines; which are evolving with the various recommendations of the World Health Organization (WHO) and the arrival of newer, more effective and safer molecules. Objective: The objective of this study was to assess the rational use of Antiretrovirals in patients treated in Kinshasa before the use of Dolutegravir within the national program in order to assess the correct use of these molecules. Methods: This work is a descriptive cross-sectional study to assess the rational use of first-line ARVs among People Living with HIV (PLHIV) in different Centers of Treatment (ATCs) in Kinshasa before the introduction of Dolutegravir. The records of patients on ARVs were randomly and rationally selected in 12 different ATCs for HIV in Kinshasa according to three centers per district in the period from June to September 2018. Information on use and consumption of ARVs, compliance with guidelines, change of therapeutic combination as well as their reasons were consulted for the present study. Results: 507 files of PLHIV were collected in the various ATCs. 274 (54.1%) were from female patients. The most represented age group was 26 to 35 years with 192 patients (37.9%). The mean duration of first-line treatment for all patients included was 16.30 ± 5.85 months. The most widely used combination of ARVs overall was TDF + 3TC + EFV at 45.4%. 305 (60.2%) PLHIV kept the same first-line treatment molecule throughout the treatment period with an average treatment duration of 12.9 ± 2.77 months. The most common combination found in this population was TDF + 3TC + EFV (69.2%). 202 (39.8%) PLHIV changed treatment molecule yet respecting the first-line combinations. The average duration of treatment for those who changed molecules was 21.43 ± 7.25 months. Before the change, 112 (55.5%) of these patients were using the ZDV + 3TC + EFV combination. After switching, 105 (52%) of the patients used the TDF + 3TC + NVP combination. The first reason for changing molecules was its unavailability (53.3%) in the ATCs. Conclusion: Although some banned molecules are still available in some treatment centers, the guidelines on first-line treatments are respected in different centers in Kinshasa.","PeriodicalId":58633,"journal":{"name":"艾滋病(英文)","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41747857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Telehealth Combined with Differentiated ART Delivery Improves ART Pick Up during COVID 19 at a Large HIV Treatment Facility in Trinidad and Tobago 远程医疗与差异化抗逆转录病毒治疗相结合,改善了特立尼达和多巴哥一家大型艾滋病毒治疗机构在2019冠状病毒病期间的抗逆转录病毒疗法接受情况
Pub Date : 2021-05-08 DOI: 10.4236/WJA.2021.112005
Nyla Lyons, W. Francis, J. Edwards, O. Lavia
Objective: To describe the implementation and outcomes of using telehealth in combination with a differentiated ART delivery model to improve HIV antiretroviral therapy pick up at a large treatment facility in Trinidad and Tobago during COVID-19. Design and Methods: Beginning in April 2020, a list of patients was generated daily prior to their scheduled ART appointments. Nurses, doctors and social workers conducted telephone consultations to first screen patients for COVID-19 symptoms, conducted brief medical and behavioural health screenings, and helped patients to identify barriers to ART retention. Patients were recommended for 1) fast track ART refill collection at facility, 2) community ART refills, and 3) ART pick-up through patient peers. The uptake and outcomes of telehealth and ART pick up were compared with the corresponding period in 2019. Data was analyzed using SPSS 21.0. Results: During the period April-June 2020, 1361 patients were identified for telephone consultations, 1084 (80%) were successfully contacted and 984 patients (88%) participated in phone session. The independent t test showed a significant increase in ART pick-up when compared to the corresponding period in 2019. 59% of patients collected via fast-track ART refill, 30% had community refills, and 11% pick-up medications through patient peers. Conclusion: Telehealth is an integral component of DSD as part of the COVID-19 response at the MRF. Understanding the medium and longer-term outcomes of Telehealth can provide additional insights on the scale up of telehealth as a component of DSD to improve ART outcomes for patients in the context of the developing countries of the Caribbean.
目的:描述在新冠肺炎期间,在特立尼达和多巴哥的一家大型治疗机构使用远程医疗与差异化抗逆转录病毒疗法提供模式相结合的实施和结果,以改进艾滋病毒抗逆转录病毒治疗。设计和方法:从2020年4月开始,每天在预约ART之前生成一份患者名单。护士、医生和社会工作者进行了电话咨询,首先对患者进行新冠肺炎症状筛查,进行了简短的医疗和行为健康筛查,并帮助患者识别保留抗逆转录病毒疗法的障碍。建议患者1)在设施中快速收集ART再填充物,2)社区ART再填充,以及3)通过患者同行收集ART。将远程医疗和抗逆转录病毒疗法的接受率和结果与2019年同期进行了比较。数据采用SPSS 21.0。结果:在2020年4月至6月期间,1361名患者被确定进行电话咨询,1084名(80%)患者被成功联系,984名患者(88%)参与了电话会议。独立t检验显示,与2019年同期相比,ART的发病率显著增加。59%的患者通过快速ART再填充收集,30%的患者通过社区再填充,11%的患者通过患者同行获取药物。结论:远程健康是DSD的一个组成部分,是MRF应对新冠肺炎的一部分。了解远程医疗的中长期结果可以为扩大远程医疗作为DSD的一个组成部分提供更多的见解,以改善加勒比发展中国家患者的ART结果。
{"title":"Telehealth Combined with Differentiated ART Delivery Improves ART Pick Up during COVID 19 at a Large HIV Treatment Facility in Trinidad and Tobago","authors":"Nyla Lyons, W. Francis, J. Edwards, O. Lavia","doi":"10.4236/WJA.2021.112005","DOIUrl":"https://doi.org/10.4236/WJA.2021.112005","url":null,"abstract":"Objective: To describe the implementation and outcomes of using telehealth in combination with a differentiated ART delivery model to improve HIV antiretroviral therapy pick up at a large treatment facility in Trinidad and Tobago during COVID-19. Design and Methods: Beginning in April 2020, a list of patients was generated daily prior to their scheduled ART appointments. Nurses, doctors and social workers conducted telephone consultations to first screen patients for COVID-19 symptoms, conducted brief medical and behavioural health screenings, and helped patients to identify barriers to ART retention. Patients were recommended for 1) fast track ART refill collection at facility, 2) community ART refills, and 3) ART pick-up through patient peers. The uptake and outcomes of telehealth and ART pick up were compared with the corresponding period in 2019. Data was analyzed using SPSS 21.0. Results: During the period April-June 2020, 1361 patients were identified for telephone consultations, 1084 (80%) were successfully contacted and 984 patients (88%) participated in phone session. The independent t test showed a significant increase in ART pick-up when compared to the corresponding period in 2019. 59% of patients collected via fast-track ART refill, 30% had community refills, and 11% pick-up medications through patient peers. Conclusion: Telehealth is an integral component of DSD as part of the COVID-19 response at the MRF. Understanding the medium and longer-term outcomes of Telehealth can provide additional insights on the scale up of telehealth as a component of DSD to improve ART outcomes for patients in the context of the developing countries of the Caribbean.","PeriodicalId":58633,"journal":{"name":"艾滋病(英文)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47859553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Assessment of the Affordability of Out-of-Pocket Payments among Some Selected People Living with HIV in Kano, Nigeria 对尼日利亚卡诺一些选定的艾滋病毒感染者自费支付能力的评估
Pub Date : 2021-05-08 DOI: 10.4236/wja.2021.112007
I. Jahun, M. Mukhtar, A. Yakubu, M. Zakirai, Bamidele Moyosola, A. Aliyu, A. Habib, Gambo Aliyu
Introduction: With an estimated 1.8 million People Living with HIV (PLHIV), Nigeria’s HIV response is still heavily donor dependent. However, with anticipated decline in donor funding for HIV/AIDS program as the country takes ownership of the program, understanding financing options for PLHIV is important. One of such financing options is affordability of out-of-pocket payments (OOP) for anti-retroviral drugs (ARV) by PLHIV. We assessed affordability of OOP payments for ARVs in Kano State, North-Western Nigeria. Methods: Four Hundred and sixty-nine PLHIV receiving donor-supported-free ARV in Kano, North Western Nigeria were systematically selected and interviewed during routine clinic visits. Affordability for ARV was assessed by a combination of variables including willingness and financial means to incur extra expense for full dose of ARV based on landing and distribution cost of 8.3 USD (about 3,000 NGN) per month dose. Results: Four hundred and sixty-nine respondents were interviewed. Of those, 72 (15.4%, 95% CI: [13.2 - 19.7]) can afford ARV OOP on monthly base. The proportion of males able to pay 3,000 NGN (8.3 USD) or more OOP for ARVs was not different from that of women (15.5% versus 15.2%). Attending school, education level, employment, monthly income and wealth have all been found to be associated with willingness and ability to pay for monthly dose of ARV OOP (p < 0.0001). Conclusion/recommendation: Majority of PLHIV in Kano State may not afford ARV OOP in the event of withdrawal of supports by international donors. Innovative sustainable financing mechanisms from domestic resources are needed for HIV program sustainability.
引言:据估计,尼日利亚有180万艾滋病毒感染者,其艾滋病毒应对措施仍然严重依赖捐助者。然而,随着国家对艾滋病毒/艾滋病项目的所有权,预计捐助者对该项目的资助将减少,了解PLHIV的融资选择很重要。其中一种融资选择是支付PLHIV抗逆转录病毒药物的自付费用。我们评估了尼日利亚西北部卡诺州抗逆转录病毒药物OOP付款的可负担性。方法:在尼日利亚西北部卡诺,系统地选择了469名接受PLHIV治疗的捐赠者支持的免费抗逆转录病毒药物,并在例行诊所访问中进行了访谈。根据每月8.3美元(约3000 NGN)的着陆和分发成本,通过包括意愿和财务手段在内的变量组合来评估抗逆转录病毒药物的可负担性,以产生全剂量抗逆转录病毒病毒药物的额外费用。结果:共采访了469名受访者。其中,72人(15.4%,95%置信区间:[13.2-19.7])每月可以负担ARV OOP。能够为抗逆转录病毒药物支付3000 NGN(8.3美元)或更多OOP的男性比例与女性比例没有差异(15.5%对15.2%),研究发现,月收入和财富都与支付月剂量抗逆转录病毒药物OOP的意愿和能力有关(p<0.0001)。结论/建议:如果国际捐助者撤回支持,卡诺州的大多数PLHIV患者可能负担不起抗逆转录病毒药OOP。艾滋病毒方案的可持续性需要利用国内资源建立创新的可持续筹资机制。
{"title":"Assessment of the Affordability of Out-of-Pocket Payments among Some Selected People Living with HIV in Kano, Nigeria","authors":"I. Jahun, M. Mukhtar, A. Yakubu, M. Zakirai, Bamidele Moyosola, A. Aliyu, A. Habib, Gambo Aliyu","doi":"10.4236/wja.2021.112007","DOIUrl":"https://doi.org/10.4236/wja.2021.112007","url":null,"abstract":"Introduction: With an estimated 1.8 million People Living with HIV (PLHIV), Nigeria’s HIV response is still heavily donor dependent. However, with anticipated decline in donor funding for HIV/AIDS program as the country takes ownership of the program, understanding financing options for PLHIV is important. One of such financing options is affordability of out-of-pocket payments (OOP) for anti-retroviral drugs (ARV) by PLHIV. We assessed affordability of OOP payments for ARVs in Kano State, North-Western Nigeria. Methods: Four Hundred and sixty-nine PLHIV receiving donor-supported-free ARV in Kano, North Western Nigeria were systematically selected and interviewed during routine clinic visits. Affordability for ARV was assessed by a combination of variables including willingness and financial means to incur extra expense for full dose of ARV based on landing and distribution cost of 8.3 USD (about 3,000 NGN) per month dose. Results: Four hundred and sixty-nine respondents were interviewed. Of those, 72 (15.4%, 95% CI: [13.2 - 19.7]) can afford ARV OOP on monthly base. The proportion of males able to pay 3,000 NGN (8.3 USD) or more OOP for ARVs was not different from that of women (15.5% versus 15.2%). Attending school, education level, employment, monthly income and wealth have all been found to be associated with willingness and ability to pay for monthly dose of ARV OOP (p < 0.0001). Conclusion/recommendation: Majority of PLHIV in Kano State may not afford ARV OOP in the event of withdrawal of supports by international donors. Innovative sustainable financing mechanisms from domestic resources are needed for HIV program sustainability.","PeriodicalId":58633,"journal":{"name":"艾滋病(英文)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43401540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medical Records Documentation of HIV/AIDS Clinical Services at Primary Health Care (PHC) Facilities and Its Implications on Continuum of Care and Operational Research in South Africa 南非初级卫生保健(PHC)设施的艾滋病毒/艾滋病临床服务医疗记录文件及其对护理连续性和业务研究的影响
Pub Date : 2021-05-08 DOI: 10.4236/wja.2021.112006
H. Fomundam, A. Tesfay, S. Mushipe, H. T. Nyambi, A. Wutoh
Background: Patients medical records are used to document care processes for communication amongst healthcare workers for continued patient management. Incomplete or inaccurate documentation can adversely affect the quality of patients’ care, leading to medication and treatment errors, increased morbidity, and mortality. Quality documentation in medical records is therefore an essential component of optimal healthcare and facilitates an individual’s continuity of care. This study aimed to assess the quality of documentation of clinical data through the review of the accuracy and completeness of clinical records among newly diagnosed HIV-positive persons. The study is a sub analysis of a prospective longitudinal study that followed a cohort of 12,413 persons who were newly diagnosed with HIV infection. Severe limitations in retrieving reliable information and data became an obstacle to our research and led the study team to conduct medical records documentation and data audit to verify the accuracy and completeness of the data for newly diagnosed HIV positive persons. Methods: A cross-sectional study was conducted using routine data generated from 75 randomly selected newly diagnosed HIV positive persons aged 12-years-old and above between June 1, 2014 and March 31, 2015 in 36 purposively selected primary health care (PHC) clinics in South Africa. The facilities were selected from three high HIV-burden districts of South Africa (Gert Sibande, uThukela and City of Johannesburg). Results: Significant differences in the accuracy and completeness of clinical records were observed between data generated through the self-assessment by the facility managers and data primarily collected through review of the patients’ clinical stationery and facility registers. 80% of the newly diagnosed HIV positive persons were not documented as screened for tuberculosis (TB) on the clinical chart and 69% of newly diagnosed clients were not clinically staged (WHO staging). Furthermore, 80% of newly diagnosed HIV positive persons’ follow up visit dates were not documented in the patient’s clinical chart. Completeness of the data elements on the case record forms ranged from as low as 26% to a maximum of 66%. It was noteworthy that all the clients’ information documented in HIV counselling and testing registers, continuum of care registers and clinical charts were only partially completed. Conclusion: Each of the health care facilities under study had some significant gaps in medical records documentation of clinical data on newly diagnosed HIV positive persons. Data and information accuracy and completeness were a serious challenge in most facilities during the period under investigation. Of interest was the inconsistency of data recorded in the HCT registers, continuum of care and clinical charts of individual patients. This is a major impediment to HIV/AIDS comprehensive care.
背景:患者医疗记录用于记录医护人员之间沟通的护理过程,以便继续进行患者管理。不完整或不准确的记录会对患者的护理质量产生不利影响,导致用药和治疗错误,增加发病率和死亡率。因此,医疗记录中的高质量文档是最佳医疗保健的重要组成部分,并促进个人护理的连续性。本研究旨在通过对新诊断的hiv阳性患者临床记录的准确性和完整性的审查来评估临床数据记录的质量。这项研究是一项前瞻性纵向研究的亚分析,该研究跟踪了12413名新诊断为艾滋病毒感染的人。在获取可靠信息和数据方面的严重限制成为我们研究的障碍,并导致研究小组对新诊断的艾滋病毒阳性者进行医疗记录文件和数据审计,以验证数据的准确性和完整性。方法:对2014年6月1日至2015年3月31日在南非36家有目的的初级卫生保健(PHC)诊所随机抽取的75名12岁及以上新诊断的HIV阳性患者的常规数据进行横断面研究。这些设施选自南非三个艾滋病毒高负担地区(格特·西班德、乌图克拉和约翰内斯堡市)。结果:通过设施管理人员自我评估产生的数据与主要通过审查患者临床文具和设施登记册收集的数据在临床记录的准确性和完整性方面存在显著差异。80%的新诊断的艾滋病毒阳性者没有在临床图表上记录为结核病筛查,69%的新诊断患者没有临床分期(世卫组织分期)。此外,80%的新诊断HIV阳性患者的随访日期没有记录在患者的临床图表中。病例记录表格上数据元素的完整性从最低的26%到最高的66%不等。值得注意的是,在艾滋病毒咨询和检测登记册、连续护理登记册和临床图表中记录的所有客户信息仅部分完成。结论:所研究的每个卫生保健机构在新诊断的艾滋病毒阳性者的临床数据的医疗记录文件方面存在一些明显的差距。在调查期间,数据和资料的准确性和完整性是大多数设施面临的严重挑战。令人感兴趣的是HCT登记册中记录的数据的不一致性,个体患者的连续护理和临床图表。这是艾滋病毒/艾滋病全面护理的一个主要障碍。
{"title":"Medical Records Documentation of HIV/AIDS Clinical Services at Primary Health Care (PHC) Facilities and Its Implications on Continuum of Care and Operational Research in South Africa","authors":"H. Fomundam, A. Tesfay, S. Mushipe, H. T. Nyambi, A. Wutoh","doi":"10.4236/wja.2021.112006","DOIUrl":"https://doi.org/10.4236/wja.2021.112006","url":null,"abstract":"Background: Patients medical records are used to document care processes for communication amongst healthcare workers for continued patient management. Incomplete or inaccurate documentation can adversely affect the quality of patients’ care, leading to medication and treatment errors, increased morbidity, and mortality. Quality documentation in medical records is therefore an essential component of optimal healthcare and facilitates an individual’s continuity of care. This study aimed to assess the quality of documentation of clinical data through the review of the accuracy and completeness of clinical records among newly diagnosed HIV-positive persons. The study is a sub analysis of a prospective longitudinal study that followed a cohort of 12,413 persons who were newly diagnosed with HIV infection. Severe limitations in retrieving reliable information and data became an obstacle to our research and led the study team to conduct medical records documentation and data audit to verify the accuracy and completeness of the data for newly diagnosed HIV positive persons. Methods: A cross-sectional study was conducted using routine data generated from 75 randomly selected newly diagnosed HIV positive persons aged 12-years-old and above between June 1, 2014 and March 31, 2015 in 36 purposively selected primary health care (PHC) clinics in South Africa. The facilities were selected from three high HIV-burden districts of South Africa (Gert Sibande, uThukela and City of Johannesburg). Results: Significant differences in the accuracy and completeness of clinical records were observed between data generated through the self-assessment by the facility managers and data primarily collected through review of the patients’ clinical stationery and facility registers. 80% of the newly diagnosed HIV positive persons were not documented as screened for tuberculosis (TB) on the clinical chart and 69% of newly diagnosed clients were not clinically staged (WHO staging). Furthermore, 80% of newly diagnosed HIV positive persons’ follow up visit dates were not documented in the patient’s clinical chart. Completeness of the data elements on the case record forms ranged from as low as 26% to a maximum of 66%. It was noteworthy that all the clients’ information documented in HIV counselling and testing registers, continuum of care registers and clinical charts were only partially completed. Conclusion: Each of the health care facilities under study had some significant gaps in medical records documentation of clinical data on newly diagnosed HIV positive persons. Data and information accuracy and completeness were a serious challenge in most facilities during the period under investigation. Of interest was the inconsistency of data recorded in the HCT registers, continuum of care and clinical charts of individual patients. This is a major impediment to HIV/AIDS comprehensive care.","PeriodicalId":58633,"journal":{"name":"艾滋病(英文)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45920227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating the Knowledge of HIV Transmission and Prevention of Mother to Child Transmission (PMTCT) of HIV among HIV-Positive Mothers Accessing Care in Military Hospital in Lagos, Nigeria 在尼日利亚拉各斯军事医院接受护理的艾滋病毒阳性母亲中,评估艾滋病毒传播知识和预防艾滋病毒母婴传播(PMTCT)
Pub Date : 2021-03-31 DOI: 10.4236/WJA.2021.111003
N. Harrison, K. Oruka, U. C. Agbaim, O. A. Adegbite, N. Okeji
Introduction: The prevention of mother-to-child transmission (PMTCT) plays a major role in limiting the number of children being infected by HIV. There is dearth of studies that explored the knowledge of HIV transmission and PMTCT among women living with HIV. Methods: This was a cross-sectional, descriptive study of HIV-positive mothers receiving medical care at the adult antiretroviral therapy (ART) clinic, 68 Nigeria Army Reference Hospital Yaba. A pre-tested structured questionnaire was used to collect information from the subjects concerning their socio-demographic, knowledge of HIV transmission and mother-to-child transmission of HIV and preventive measures. SPSS v23 was used for data analysis. Results: Out of the 374 participants, 282 (75.4%) were aware that HIV can be transmitted to an unborn baby from the positive mother. Of these, 240 (85.1%) were well-informed that increase mother’s viral load can increase the chances of mother-to-child transmission. 268 (95%) understood that giving of antiretroviral drugs during and after pregnancy can lower transmission risk, while 254 (90.1%) saw the use of breast milk substitutes as another prevention strategy. There was statistically significant association between the respondents’ knowledge of PMTCT and their husbands’/partners’ awareness of their HIV status. Conclusion: In conclusion, our study demonstrated a good knowledge of HIV transmission, MTCT and PMTCT among women who were receiving ART in our centre. Disclosure is a significant factor found to be associated with PMTCT knowledge. More studies can also explore if the observations in our study with women living with HIV will be comparable in similar population in different settings.
引言:预防母婴传播在限制感染艾滋病毒的儿童人数方面发挥着重要作用。缺乏探索艾滋病毒感染者中艾滋病毒传播和预防母婴传播知识的研究。方法:这是一项横断面描述性研究,研究对象是在亚巴68尼日利亚陆军参考医院成人抗逆转录病毒疗法(ART)诊所接受医疗护理的HIV阳性母亲。使用预先测试的结构化问卷从受试者那里收集有关其社会人口统计、艾滋病毒传播知识、艾滋病毒母婴传播和预防措施的信息。数据分析采用SPSS v23软件。结果:在374名参与者中,282人(75.4%)意识到艾滋病毒可以从阳性母亲传染给未出生的婴儿。其中,240人(85.1%)充分了解母亲病毒载量的增加会增加母婴传播的机会。268人(95%)认为在怀孕期间和怀孕后服用抗逆转录病毒药物可以降低传播风险,254人(90.1%)认为使用母乳替代品是另一种预防策略。受访者对预防母婴传播的了解与其丈夫/伴侣对其艾滋病毒状况的认识之间存在统计学上的显著关联。结论:总之,我们的研究表明,在我们中心接受抗逆转录病毒治疗的妇女中,他们对艾滋病毒传播、MTCT和PMTCT有很好的了解。披露是与PMTCT知识相关的一个重要因素。更多的研究也可以探索我们对感染艾滋病毒的女性的研究中的观察结果在不同环境下的相似人群中是否具有可比性。
{"title":"Evaluating the Knowledge of HIV Transmission and Prevention of Mother to Child Transmission (PMTCT) of HIV among HIV-Positive Mothers Accessing Care in Military Hospital in Lagos, Nigeria","authors":"N. Harrison, K. Oruka, U. C. Agbaim, O. A. Adegbite, N. Okeji","doi":"10.4236/WJA.2021.111003","DOIUrl":"https://doi.org/10.4236/WJA.2021.111003","url":null,"abstract":"Introduction: The prevention of mother-to-child transmission (PMTCT) plays a major role in limiting the number of children being infected by HIV. There is dearth of studies that explored the knowledge of HIV transmission and PMTCT among women living with HIV. Methods: This was a cross-sectional, descriptive study of HIV-positive mothers receiving medical care at the adult antiretroviral therapy (ART) clinic, 68 Nigeria Army Reference Hospital Yaba. A pre-tested structured questionnaire was used to collect information from the subjects concerning their socio-demographic, knowledge of HIV transmission and mother-to-child transmission of HIV and preventive measures. SPSS v23 was used for data analysis. Results: Out of the 374 participants, 282 (75.4%) were aware that HIV can be transmitted to an unborn baby from the positive mother. Of these, 240 (85.1%) were well-informed that increase mother’s viral load can increase the chances of mother-to-child transmission. 268 (95%) understood that giving of antiretroviral drugs during and after pregnancy can lower transmission risk, while 254 (90.1%) saw the use of breast milk substitutes as another prevention strategy. There was statistically significant association between the respondents’ knowledge of PMTCT and their husbands’/partners’ awareness of their HIV status. Conclusion: In conclusion, our study demonstrated a good knowledge of HIV transmission, MTCT and PMTCT among women who were receiving ART in our centre. Disclosure is a significant factor found to be associated with PMTCT knowledge. More studies can also explore if the observations in our study with women living with HIV will be comparable in similar population in different settings.","PeriodicalId":58633,"journal":{"name":"艾滋病(英文)","volume":"11 1","pages":"25-40"},"PeriodicalIF":0.0,"publicationDate":"2021-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49278436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
An Assessment of the Social, Cultural, and Economical Barriers to Option B+ Retention and Their Solutions in Malawi: A Review 马拉维对B+选项保留的社会、文化和经济障碍及其解决方案的评估:综述
Pub Date : 2021-03-31 DOI: 10.4236/WJA.2021.111002
Jamie Yoon, David S. Chung, Michelle Kim, Kunmin Kim, Sang Heon Lee, Tae Youn Kim, Hark Joon Lee, S. Moon, Jooheon Park, P. Chung, T. Nyirenda
Malawi has one of the highest rates of HIV prevalence in the world, and accounts for 4% of the total number of people living in sub-Saharan Africa with HIV. Approximately one million people in Malawi were living with HIV in 2016, with 24,000 HIV-related deaths. The Option B+ program, first implemented in Malawi, aimed to initiate ART for all pregnant women, regardless of their CD4 cell count or disease stage. This study serves to analyze and assess the effectiveness of Option B+ retention, in relation to the facilitation of how various social and cultural barriers were handled. A literature review of 29 publications was conducted. Careful evaluation of various studies indicates that although there is a myriad of reasons explaining low levels of retention, the women who were at the highest risk for low retention were young pregnant women who were treated on the same day of HIV-diagnosis. Solutions focused around women and their partners or communities showed promising evidence of success in increasing adherence, as these strategies likely provided women reliable social and emotional support to address major barriers to retention such as a lack of support from male partners, ineffective education from healthcare workers, or stigma towards their HIV disclosure statue.
马拉维是世界上艾滋病毒感染率最高的国家之一,占撒哈拉以南非洲艾滋病毒感染者总数的4%。2016年,马拉维约有100万人感染艾滋病毒,24000人死于艾滋病毒。首次在马拉维实施的B+方案旨在为所有孕妇启动抗逆转录病毒疗法,无论其CD4细胞计数或疾病分期如何。本研究旨在分析和评估选项B+保留的有效性,以及如何处理各种社会和文化障碍。对29种出版物进行了文献综述。对各种研究的仔细评估表明,尽管有多种原因可以解释低滞留率,但低滞留率风险最高的女性是在确诊艾滋病毒的同一天接受治疗的年轻孕妇。以女性及其伴侣或社区为重点的解决方案显示出了在提高依从性方面取得成功的有希望的证据,因为这些策略可能为女性提供了可靠的社会和情感支持,以解决留住女性的主要障碍,如缺乏男性伴侣的支持、医护人员的无效教育或对其艾滋病毒披露雕像的污名。
{"title":"An Assessment of the Social, Cultural, and Economical Barriers to Option B+ Retention and Their Solutions in Malawi: A Review","authors":"Jamie Yoon, David S. Chung, Michelle Kim, Kunmin Kim, Sang Heon Lee, Tae Youn Kim, Hark Joon Lee, S. Moon, Jooheon Park, P. Chung, T. Nyirenda","doi":"10.4236/WJA.2021.111002","DOIUrl":"https://doi.org/10.4236/WJA.2021.111002","url":null,"abstract":"Malawi has one of the highest rates of HIV prevalence in the world, and accounts for 4% of the total number of people living in sub-Saharan Africa with HIV. Approximately one million people in Malawi were living with HIV in 2016, with 24,000 HIV-related deaths. The Option B+ program, first implemented in Malawi, aimed to initiate ART for all pregnant women, regardless of their CD4 cell count or disease stage. This study serves to analyze and assess the effectiveness of Option B+ retention, in relation to the facilitation of how various social and cultural barriers were handled. A literature review of 29 publications was conducted. Careful evaluation of various studies indicates that although there is a myriad of reasons explaining low levels of retention, the women who were at the highest risk for low retention were young pregnant women who were treated on the same day of HIV-diagnosis. Solutions focused around women and their partners or communities showed promising evidence of success in increasing adherence, as these strategies likely provided women reliable social and emotional support to address major barriers to retention such as a lack of support from male partners, ineffective education from healthcare workers, or stigma towards their HIV disclosure statue.","PeriodicalId":58633,"journal":{"name":"艾滋病(英文)","volume":"11 1","pages":"15-24"},"PeriodicalIF":0.0,"publicationDate":"2021-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44539096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Viral Suppression in Adult Nigerians in a Regional Antiretroviral Therapy Programme: A Cross Sectional Descriptive Study 区域抗逆转录病毒治疗计划中尼日利亚成年人的病毒抑制:一项横断面描述性研究
Pub Date : 2021-03-15 DOI: 10.4236/WJA.2021.111001
E. Isaac, A. Ajani, A. J. Difa, J. Aremu, Oyeniyi Christianah Oluwaseun, Muhammad Hassan
Background: The adult ART (antiretroviral therapy) programme started in Nigeria in 2002. After many years of ART in the country, the National implementation plan for the scale up of viral load testing was launched in 2016. Viral load estimation is the most important indicator of ART response. Aim: To describe viral suppression in adults on the HIV ART programme Material & methods: Viral load blood samples of 9450 adults on highly active antiretroviral therapy living with HIV from 4 states within Nigeria were analyzed for HIV RNA in Polymerase Chain Reaction laboratory of the Federal Teaching Hospital, Gombe between December 2017 and December 2019. Results: Males were 2577/9450 (27.3%) and 6873 (72.7%) females. Adults aged 26 - 45 years constituted 69.5% (6572). Viral load test was primarily routine in 96.3% (9098). ART was AZT/3TC/NVP in 52.5% (4962); TDF/3TC/EFV in 46.3% (4375). 48.3% (4568/9450) adults had received HAART for 1 - 5 years; 7.4% (699) for 6 months but 10 years. The most recent CD4 count before viral load request was ≥1000/μL in 6.5% (612) of adults; 500 - 999/μL in 38.6% (3651); 350 - 499 μL in 23.2% (2195) and 1000 c/ml in 22.8% (587/2577) males and 23.0% (1580/6873) females. Of adults aged 19 - 25 years, 28.4% (211/743) had viral load >1000 c/ml; 23.5% (1544/6572); 20.0% (294/1473); 17.8% (93/523) and 18.0% (25/139) aged 26 - 45 years, 46 - 55 years; 56 - 65 years and >65 years also had viral load >1000 c/ml (p value 1000 c/ml in 26.0% (182/699) of adults on HAART for 6 months - 1 year and 21.3% (975/4568) after receiving HAART for 1 - 5 years. 24.9% (885/3551) and 19.8% (125/632) adults had viral load > 1000 c/ml after receiving HAART for 6 - 10 and >10 years respectively. (p value < 0.001) Conclusion: Over all viral suppression of 77% in our study is high but fell below the WHO threshold of 90%. ART programme in Nigeria requires strengthening.
背景:尼日利亚成人抗逆转录病毒治疗方案于2002年启动。经过该国多年的抗逆转录病毒治疗,2016年启动了扩大病毒载量检测的国家实施计划。病毒载量估计是抗逆转录病毒治疗反应最重要的指标。材料和方法:2017年12月至2019年12月,在贡贝联邦教学医院聚合酶链反应实验室,对尼日利亚4个州接受高活性抗逆转录病毒治疗的9450名艾滋病毒感染者的病毒载量血液样本进行了HIV RNA分析。结果:男性2577/9450例(27.3%),女性6873例(72.7%)。26 - 45岁的成年人占69.5%(6572)。96.3%(9098)的患者进行常规病毒载量检测。AZT/3TC/NVP占52.5%(4962例);TDF/3TC/EFV占46.3%(4375)。48.3%(4568/9450)成人接受HAART治疗1 - 5年;7.4%(699)为6个月,但10年。6.5%(612)成人在病毒载量请求前CD4≥1000/μL;500 ~ 999/μL占38.6% (3651);350 ~ 499 μL, 23.2% (2195); 1000 μL, 22.8% (587/2577); 23.0% (1580/6873);在19 - 25岁的成年人中,28.4%(211/743)的病毒载量为1000 c/ml;23.5% (1544/6572);20.0% (294/1473);26 ~ 45岁17.8%(93/523),46 ~ 55岁18.0% (25/139);56 - 65岁和55 - 65岁的成年人在HAART治疗6个月- 1年的26.0%(182/699)和接受HAART治疗1 - 5年后的21.3%(975/4568)的病毒载量>为1000 c/ml (p值为1000 c/ml)。24.9%(885/3551)和19.8%(125/632)的成人在接受HAART治疗6 ~ 10年和10年后的病毒载量分别为>0 000 c/ml和>0 000 c/ml。(p值< 0.001)结论:在我们的研究中,77%的病毒抑制率很高,但低于WHO阈值90%。尼日利亚的抗逆转录病毒治疗方案需要加强。
{"title":"Viral Suppression in Adult Nigerians in a Regional Antiretroviral Therapy Programme: A Cross Sectional Descriptive Study","authors":"E. Isaac, A. Ajani, A. J. Difa, J. Aremu, Oyeniyi Christianah Oluwaseun, Muhammad Hassan","doi":"10.4236/WJA.2021.111001","DOIUrl":"https://doi.org/10.4236/WJA.2021.111001","url":null,"abstract":"Background: The adult ART (antiretroviral therapy) programme started in Nigeria in 2002. After many years of ART in the country, the National implementation plan for the scale up of viral load testing was launched in 2016. Viral load estimation is the most important indicator of ART response. Aim: To describe viral suppression in adults on the HIV ART programme Material & methods: Viral load blood samples of 9450 adults on highly active antiretroviral therapy living with HIV from 4 states within Nigeria were analyzed for HIV RNA in Polymerase Chain Reaction laboratory of the Federal Teaching Hospital, Gombe between December 2017 and December 2019. Results: Males were 2577/9450 (27.3%) and 6873 (72.7%) females. Adults aged 26 - 45 years constituted 69.5% (6572). Viral load test was primarily routine in 96.3% (9098). ART was AZT/3TC/NVP in 52.5% (4962); TDF/3TC/EFV in 46.3% (4375). 48.3% (4568/9450) adults had received HAART for 1 - 5 years; 7.4% (699) for 6 months but 10 years. The most recent CD4 count before viral load request was ≥1000/μL in 6.5% (612) of adults; 500 - 999/μL in 38.6% (3651); 350 - 499 μL in 23.2% (2195) and 1000 c/ml in 22.8% (587/2577) males and 23.0% (1580/6873) females. Of adults aged 19 - 25 years, 28.4% (211/743) had viral load >1000 c/ml; 23.5% (1544/6572); 20.0% (294/1473); 17.8% (93/523) and 18.0% (25/139) aged 26 - 45 years, 46 - 55 years; 56 - 65 years and >65 years also had viral load >1000 c/ml (p value 1000 c/ml in 26.0% (182/699) of adults on HAART for 6 months - 1 year and 21.3% (975/4568) after receiving HAART for 1 - 5 years. 24.9% (885/3551) and 19.8% (125/632) adults had viral load > 1000 c/ml after receiving HAART for 6 - 10 and >10 years respectively. (p value < 0.001) Conclusion: Over all viral suppression of 77% in our study is high but fell below the WHO threshold of 90%. ART programme in Nigeria requires strengthening.","PeriodicalId":58633,"journal":{"name":"艾滋病(英文)","volume":"11 1","pages":"720-726"},"PeriodicalIF":0.0,"publicationDate":"2021-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45143646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
An Evidence-Based Management Approach to HIV/AIDS in Nigeria 尼日利亚艾滋病毒/艾滋病循证管理方法
Pub Date : 2021-01-01 DOI: 10.4236/wja.2021.113010
T. Mosugu
{"title":"An Evidence-Based Management Approach to HIV/AIDS in Nigeria","authors":"T. Mosugu","doi":"10.4236/wja.2021.113010","DOIUrl":"https://doi.org/10.4236/wja.2021.113010","url":null,"abstract":"","PeriodicalId":58633,"journal":{"name":"艾滋病(英文)","volume":"59 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70851630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of the Third 90 of the 90-90-90 Cascade for the Period 2019-2020 in the Central African Republic 中非共和国2019-2020年期间90-90-90级联计划第三阶段90的评估
Pub Date : 2021-01-01 DOI: 10.4236/wja.2021.114014
Gilles Ngaya, B. Yambiyo, Alain Farra, Pulchérie Pélembi, A. Béré, D. Golongba, S. Kamadom, A. Berlioz-Arthaud
Introduction In Central-African Republic, according to UNAIDS in 2019, out of approximately 100,000 people living with HIV, 70% (72,000) knew their HIV status and 47,000 (46%) were on ARV therapy; however, there is a paucity of data on viral load suppression in people on ARV therapy. The objective of this study was to assess the third 90 of the UNAIDS strategy for the years 2019 and 2020 in the CAR. Methods We analyzed the available viral load data extracted from the data base of the medical analysis laboratory (SYSLAM) of the Institut Pasteur of Bangui for the years 2019 and 2020. The viral loads were determined based on plasma collected in an EDTA tube with Cepheid’s GeneXpert 16-module controllers. Viral load data were extracted from SYSLAM, converted to Excel format, and analyzed with STATA version 14 software. The significance threshold for the statistical tests was set at 5%. Results This study included 22,895 patients, of who 72% were female. The average age was 40.82 years, and the majority of the patients (80%) came from the city of Bangui. Regarding the virological parameters associated with this study, 66% of the patients had significant viral load suppression according to the WHO recommendations and 34% were in virological failure. Patients over 50 years of age (71.85%) and age group 40 49 years (69.25%) recorded significant levels of viral load suppression. On the other hand, 63.45% of patients under 18 years of age had virological failure. All of these results were statistically significant (p < 0.005). Conclusion There should be a concerted effort, to make viral load accessible and available to all patients receiving ARV treatment in the CAR and the management of HIV/AIDS infection of children and adolescents should be given special attention. How to cite this paper: Ngaya, G.S.L., Yambiyo, B.M., Farra, A., Pelembi, P., Bere, A., Golongba, D., Kamadom, S. and BerliozArthaud, A. (2021) Evaluation of the Third 90 of the 90-90-90 Cascade for the Period 2019-2020 in the Central African Republic. World Journal of AIDS, 11, 189-198. https://doi.org/10.4236/wja.2021.114014 Received: October 12, 2021 Accepted: December 27, 2021 Published: December 30, 2021 Copyright © 2021 by author(s) and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY 4.0). http://creativecommons.org/licenses/by/4.0/ Open Access G. S. L. Ngaya et al. DOI: 10.4236/wja.2021.114014 190 World Journal of AIDS
在中非共和国,根据联合国艾滋病规划署2019年的数据,在大约10万名艾滋病毒感染者中,70%(7.2万人)知道自己感染了艾滋病毒,4.7万人(46%)正在接受抗逆转录病毒治疗;然而,在接受抗逆转录病毒治疗的人群中,缺乏病毒载量抑制的数据。本研究的目的是评估联合国艾滋病规划署2019年和2020年中非共和国战略的第三个目标。方法对班吉巴斯德研究所医学分析实验室(SYSLAM)数据库中提取的2019年和2020年病毒载量数据进行分析。利用造父变星的GeneXpert 16模块控制器采集EDTA管中的血浆,确定病毒载量。从SYSLAM中提取病毒载量数据,转换为Excel格式,使用STATA version 14软件进行分析。统计学检验的显著性阈值设为5%。结果共纳入22,895例患者,其中72%为女性。平均年龄40.82岁,大部分患者(80%)来自班吉市。关于与本研究相关的病毒学参数,根据世卫组织的建议,66%的患者有明显的病毒载量抑制,34%的患者病毒学失败。50岁以上患者(71.85%)和40 - 49岁年龄组(69.25%)记录了显著水平的病毒载量抑制。另一方面,18岁以下患者的病毒学失败率为63.45%。这些结果均有统计学意义(p < 0.005)。结论应共同努力,使中非共和国所有接受抗逆转录病毒治疗的患者都能获得病毒载量,并应特别重视儿童和青少年艾滋病毒/艾滋病感染的管理。如何引用本文:Ngaya, g.s.l., Yambiyo, b.m., Farra, A., Pelembi, P., Bere, A., Golongba, D., Kamadom, S.和BerliozArthaud, A.(2021)中非共和国2019-2020年期间90-90-90级反应的第三个90的评估。世界艾滋病杂志,11,189-198。https://doi.org/10.4236/wja.2021.114014收稿日期:2021年10月12日收稿日期:2021年12月27日出版日期:2021年12月30日版权所有©作者与科研出版公司。本作品采用知识共享署名国际许可协议(CC BY 4.0)。http://creativecommons.org/licenses/by/4.0/ Open Access g.s.l. Ngaya等。DOI: 10.4236/wja.2021.114014 190世界艾滋病杂志
{"title":"Evaluation of the Third 90 of the 90-90-90 Cascade for the Period 2019-2020 in the Central African Republic","authors":"Gilles Ngaya, B. Yambiyo, Alain Farra, Pulchérie Pélembi, A. Béré, D. Golongba, S. Kamadom, A. Berlioz-Arthaud","doi":"10.4236/wja.2021.114014","DOIUrl":"https://doi.org/10.4236/wja.2021.114014","url":null,"abstract":"Introduction In Central-African Republic, according to UNAIDS in 2019, out of approximately 100,000 people living with HIV, 70% (72,000) knew their HIV status and 47,000 (46%) were on ARV therapy; however, there is a paucity of data on viral load suppression in people on ARV therapy. The objective of this study was to assess the third 90 of the UNAIDS strategy for the years 2019 and 2020 in the CAR. Methods We analyzed the available viral load data extracted from the data base of the medical analysis laboratory (SYSLAM) of the Institut Pasteur of Bangui for the years 2019 and 2020. The viral loads were determined based on plasma collected in an EDTA tube with Cepheid’s GeneXpert 16-module controllers. Viral load data were extracted from SYSLAM, converted to Excel format, and analyzed with STATA version 14 software. The significance threshold for the statistical tests was set at 5%. Results This study included 22,895 patients, of who 72% were female. The average age was 40.82 years, and the majority of the patients (80%) came from the city of Bangui. Regarding the virological parameters associated with this study, 66% of the patients had significant viral load suppression according to the WHO recommendations and 34% were in virological failure. Patients over 50 years of age (71.85%) and age group 40 49 years (69.25%) recorded significant levels of viral load suppression. On the other hand, 63.45% of patients under 18 years of age had virological failure. All of these results were statistically significant (p < 0.005). Conclusion There should be a concerted effort, to make viral load accessible and available to all patients receiving ARV treatment in the CAR and the management of HIV/AIDS infection of children and adolescents should be given special attention. How to cite this paper: Ngaya, G.S.L., Yambiyo, B.M., Farra, A., Pelembi, P., Bere, A., Golongba, D., Kamadom, S. and BerliozArthaud, A. (2021) Evaluation of the Third 90 of the 90-90-90 Cascade for the Period 2019-2020 in the Central African Republic. World Journal of AIDS, 11, 189-198. https://doi.org/10.4236/wja.2021.114014 Received: October 12, 2021 Accepted: December 27, 2021 Published: December 30, 2021 Copyright © 2021 by author(s) and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY 4.0). http://creativecommons.org/licenses/by/4.0/ Open Access G. S. L. Ngaya et al. DOI: 10.4236/wja.2021.114014 190 World Journal of AIDS","PeriodicalId":58633,"journal":{"name":"艾滋病(英文)","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70852290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
艾滋病(英文)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1